
ãã«ãã¬ã³ãºã»ãã«ã¹ã»ãã£ãã§ã³ã¹ã®ç§åŠè ïŒCDCãšFDAã®æ°åã³ããã¯ã¯ãã³å®å šæ§ç£èŠã¯ã䟮蟱çã§ãå€ãã®äººãè² å·ããŠããã
å èšäºã¯ãã¡ããã/Click here to read the original article.
ãã€ãã³æ¿æš©äžã®é£éŠä¿å¥åœå±ã¯ãã¯ã¯ãã³å±éåŸã®COVID-19ã¯ã¯ãã³ã®å®å šæ§ã·ã°ãã«ã®ç£èŠã«ãããŠãã²ã©ã倱æããââæ¬æ¥ããã«ãã¬ã³ãºã»ãã«ã¹ã»ãã£ãã§ã³ã¹ã®äžçŽç ç©¶ç§åŠè ã«ãŒã«ã»ã€ããããã¹ããŒæ°ãè°äŒèšŒèšã§ããè¿°ã¹ããæ¿åºã®ã¯ã¯ãã³å®å šæ§ç£èŠã¯ã䟮蟱çã§ãããå€ãã®äººãå·ã€ããŠããããšãã€ããããã¹ããŒæ°ã¯æžé¢èšŒèšã§èšããã
ãã€ãã³æ¿æš©äžã®é£éŠä¿å¥åœå±ã¯ãCOVID-19ã¯ã¯ãã³ã®å®å šæ§ã·ã°ãã«ãæ¢ãããšã«èãã倱æããââæ¬æ¥ããã«ãã¬ã³ã»ãã«ã¹ã»ãã£ãã§ã³ã¹ïŒCHDïŒã®äžçŽç ç©¶ç§åŠè ã«ãŒã«ã»ã€ããããã¹ããŒãè°äŒèšŒèšã§ããè¿°ã¹ãã
ãé廿°å¹Žéã®æ¿åºã®ã¯ã¯ãã³å®å šæ§ç£èŠã¯äŸ®èŸ±çã§ãããå€ãã®äººã ãå·ã€ããŠããããšãã€ããããã¹ããŒã¯æžé¢ã®èšŒèšã§èšããã
æèšãåŠã°ãªããã°æŽå²ã¯ç¹°ãè¿ãããããšã€ããããã¹ããŒã¯èŠåããã
ãCOVID-19ã®ãã³ãããã¯ã¯ãç±³åœã§100人以äžãäžçã§1,000人以äžã®åäžé·è ãçã¿åºããããšã€ããããã¹ããŒã¯æžãããããããŸã§å²ãããã®ã¯ãå¿ ãç¹°ãè¿ããããã
ã¯ã·ã³ãã³å€§åŠå»åŠéšã§çç©å»åŠã»å¥åº·æ å ±åŠã®å士å·ãæããã€ããããã¹ããŒã¯ãç±³äžé¢åžžä»»èª¿æ»å°å§å¡äŒã®å ¬èŽäŒããã¹ã¯ãå€ããŠïŒãã€ãã³æ¿æš©ã®ä¿å¥åœå±è ã¯ããã«æå³çã«COVID-19ã¯ã¯ãã³å®å šæ§ã·ã°ãã«ã«ç®ãã€ã¶ã£ãããã§èšŒäººãšããŠèšŒèšããã
å ¬èŽäŒã®æ°æéåãåå°å§å¡äŒå§å¡é·ã®ãã³ã»ãžã§ã³ãœã³äžé¢è°å¡ïŒå ±åå ã»ãŠã£ã¹ã³ã³ã·ã³å·éžåºïŒã¯ããã€ãã³æ¿æš©æã®é£éŠä¿å¥åœå±è ããVAERSã«ãããCOVID-19ã¯ã¯ãã³æ¥çš®ã®ã·ã°ãã«æ€åºã®ããã®æå 端ã®çµ±èšããŒã«ã®äœ¿çšãæåŠããŠããããšã詳述ããå ±åæžãå ¬è¡šããââåœå±è ãã¯ãèªåãã¡ã䜿çšããŠããããŒã«ãçªç¶æ»ãå«ãå®å šæ§ã·ã°ãã«ãæŸããªãã»ã©å£ããŠãããšèªèããŠããã«ãããããããã§ããã
çŽ600ããŒãžã®é»åã¡ãŒã«ãåŒçšãããžã§ã³ãœã³ã®å ±åæžã¯ã2021幎ã«ç±³é£åå»è¬åå±ïŒFDAïŒã®åœå±è ããã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒã«ãããCOVID-19ã¯ã¯ãã³å·å®³å ±åãåæããããã«ãã®æå 端ããŒã«ãçšããããšããFDAã®ç ç©¶è ã«å¯ŸããŠãå³æäžæ¢ãïŒcease and desistïŒããããåœããŠããããšãæããã«ããã
ãžã§ã³ãœã³è°å¡ã¯ãCOVID-19ã¯ã¯ãã³ã®å®å šæ§èšé²ããã³ãã³ãããã¯é¢é£ã®ã³ãã¥ãã±ãŒã·ã§ã³ã«ã€ããŠã2025幎1æã«ç±³ä¿å¥çŠç¥çã«å¬åç¶ãçºåºããåŸã«ããããã®é»åã¡ãŒã«ãå ¥æããã
FDAã¯VAERSã«ãããCOVIDã¯ã¯ãã³æå®³äºè±¡å ±åã«ãç²ç®ãã ã£ã
蚌èšã®äžã§ããžã£ããããŠã¹ããŒæ°ã¯ãé£éŠæ¿åºã®3ã€ã®ã¯ã¯ãã³å®å šæ§ç£èŠã·ã¹ãã ââVAERSãV-safeãVaccine Safety DatalinkïŒVSDïŒââã®ããããã«ãèœãšã穎ãããããCOVID-19ã¯ã¯ãã³ãä»ã®ã¯ã¯ãã³ã®å®å šæ§åé¡ãé©åã«è©äŸ¡ããããšã«ã倱æããããšè©³è¿°ããã
ã¯ã¯ãã³å®å šæ§ç£èŠã®å€±æã¯ãèµ·ããåŸãããå®éã«èµ·ããŠã壿» çã«ãªãåŸãããšåœŒã¯è¿°ã¹ãã
ããšãã°FDAã¯ãæ©èœããªããšããã£ãŠããææ³ã§COVID-19ã¯ã¯ãã³å ±åãç£èŠããããšã«åºå·ããããã¡ã€ã¶ãŒãšã¢ãã«ãã®COVID-19ã¯ã¯ãã³ã®ãããªé¡äŒŒã¯ã¯ãã³ãããŒã¿ã»ããã«å«ãŸãããšããã®ææ³ã¯äžæ£ç¢ºãªçµæãããããå¯èœæ§ãé«ãããšãFDAã¯ç¥ã£ãŠãããããã¯ãã¹ãã³ã°ãšåŒã°ããã
ãFDAã¯COVID-19ã¯ã¯ãã³ã®æå®³äºè±¡ã«å®å šã«ç²ç®ã ã£ãããšãžã£ããããŠã¹ããŒæ°ã¯èšããã圌ã¯ãFDAã¯ãã¹ãã³ã°ãèæ ®ããæ¹è¯ãããçµ±èšææ³ãçšããããšãã§ããã¯ãã ãšè¿°ã¹ãã
Drug Safetyèªã«2022å¹Žã«æ²èŒãããæ»èªæžã¿è«æã¯ããã®æ¹è¯ææ³ããFDAã®æ§æ¥ææ³ã§ã¯èŠéããããå¿èçªç¶æ»ããã«éº»çºãèºæ¢å¡ãå«ãçŽ25ã®çµ±èšçã«ææãªCOVID-19ã¯ã¯ãã³å®å šæ§ã·ã°ãã«ãæ€åºããããšã瀺ããã
Earlierã«The Defenderã®ã€ã³ã¿ãã¥ãŒã§ããžã£ããããŠã¹ããŒæ°ã¯ãFDAãæ§æ¥ææ³ã®äœ¿çšãç¶ããããšããªãããã»ã©æå®³ã ã£ãã®ãã説æããã
ãå€èŠãå°é¢ã®äœããèŠã€ããªããã°ãªããªããšæ³åããŠã¿ãŠãã ããããšãããæäžé»ç¯ãæã€ä»£ããã«ããµã³ã°ã©ã¹ããããŠããã®ã§ããæã«ãªã£ãŠã圌ã¯äœãèŠã€ãããªãã£ããšèšããŸãã確ãã«ããã§ãããããã¯èŠçã劚ããéå ·ã䜿ã£ãŠããããã§ããã
OpenVAERSã«ãããšã3æ27æ¥çŸåšãCOVID-19ã¯ã¯ãã³æ¥çš®åŸã«VAERSãžå ±åãããæå®³äºè±¡ã¯1,675,590ä»¶ã«äžãããã®æ°ã«ã¯ã39,077ä»¶ãè¶ ããæ»äº¡å ±åã29,200ä»¶ã®å¿ççãŸãã¯å¿èçã®å ±åã18,009ä»¶ã®ãã«éº»çºã®å ±åãå«ãŸããã
2025幎11æã«å®æœãããå šåœèª¿æ»ã§ã¯ãCOVID-19ã¯ã¯ãã³ãåããç±³åœæäººã®ããã10人ã«1人ããé倧ãªãå¯äœçšãçµéšããããšã倿ããã
V-safeã¯ãåãã«è¶³ããªããããŒã¿ãéããããèšèšãããŠãã
ãžã£ããããŠã¹ããŒæ°ã¯è°å¡ãã«ãç±³åœçŸç äºé²ç®¡çã»ã³ã¿ãŒïŒCDCïŒã®COVID-19ã¯ã¯ãã³å®å šæ§ç£èŠããŒã«ã§ããV-safeã¯ãèª°ãæ¬åœã«æ°ã«ããªããåãã«è¶³ããªããæ å ±ã ããåéããããèšèšãããŠãããšè¿°ã¹ãã
V-safeã¢ããªã¯ãCOVID-19ã¯ã¯ãã³æ¥çš®è ã«å¯Ÿããæ¥çš®åŸã«ã©ã®ãããªå¯åå¿ããã£ããïŒããããã°ïŒã瀺ããã§ãã¯ããã¯ã¹ãéžã°ããã
ãããããã®éžæè¢ã¯ãæªå¯ãé çãé¢ç¯çãçèçãŸãã¯äœã®çã¿ãåŠæ æãç²åŽãåãæ°ãååãäžç¢ãè ¹çãçºç¹ãšãã£ããå€ãã®äººããåãã«è¶³ããªãããšèŠãªãäžè¬çãªçæçã¯ã¯ãã³å¯åå¿ã«éãããŠããã
ããæ·±å»ãªåé¡ãçµéšããå Žåã¯ãããã®ä»ãã®ããã¹ãæ¬ã«æå ¥åããªããã°ãªããªãã£ãããšãžã£ããããŠã¹ããŒæ°ã¯ææããã圌ã¯ããè¿°ã¹ãã
ãããã®ä»ãã®èªç±èšè¿°æ¬ã«ãå»çäžã®èšºæãèŠããç æ ã§ãããå¿ççããšå ¥åãã人ã366人ããããšããç§ãã¡ã¯æŠæ ãšãšãã«èŠåºããŸããããã®æŠæ ã¯ããèžçããšããã®ä»ãã®èªç±èšè¿°æ¬ã«å ¥åããç»é²è ãã»ãŒ5äžäººã«ã®ãŒãããšã§äžå±€åŒ·ãŸããŸããã
ã¯ã¯ãã³ã»ã»ãŒããã£ã»ããŒã¿ãªã³ã¯ïŒVSDïŒã¯ç¬ç«ç ç©¶è ã«ã¯éåæã
Jablonowskiæ°ã¯ãŸãã13ã®çµ±ååãã«ã¹ã±ã¢çµç¹ããã®æ£è æ å ±ãéçŽãã1,550äžäººä»¥äžãã«ããŒããå ±åããŒã¿ããŒã¹ã§ããVSDããããã«å ¬è¡ã«å¯ŸããŠäžååã§ãããã詳述ããŸããã
Jablonowskiæ°ã«ãããšãVSDã®ããŒã¿ã¯ãã»ãŒãªã¢ã«ã¿ã€ã ã§ã¯ã¯ãã³å®å šæ§ã®åé¡ãæ€åºããããã«è¡šåãã¯å©çšå¯èœã§ãã
åé¡ã¯ããã®ããŒã¿ãé²èЧã§ããç§åŠè ãããäžæ¡ãã«éãããŠããããšã§ããJablonowskiæ°ã¯æ¬¡ã®ããã«è¿°ã¹ãŸããã
ããã®äœçŸäžãã«ãã®çŽçšè è³éã§éå¶ãããŠãããªãœãŒã¹ã¯ã13ã®ãããžãã»ã±ã¢ã»ãªãŒã¬ããŒãŒã·ã§ã³ïŒMCOïŒãŸãã¯é£éŠæ¿åºã®å€éšã«ããç§åŠè ã«ã¯ã13ã®MCOãã¹ãŠããæ¿èªãããç¬ç«IRBç¬ç«å¯©æ»å§å¡äŒïŒœç³è«ãšããããžã§ã¯ãããšã«æšå®25äžãã«ããªããã°å©çšã§ããŸãããã
èšãæããã°ãç¬ç«ç ç©¶è ã¯å®è³ªçã«ãã®ããŒã¿ã®åæããæé€ãããŠããŸãããéææ§ã¯ãŸã£ããéæäžå¯èœã§ãããšJablonowskiæ°ã¯è¿°ã¹ãŸããã
Jablonowskiæ°ã®åé é³è¿°ã¯ãã¡ããã芧ãã ããïŒ